Cargando…
Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure
BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a ne...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122761/ https://www.ncbi.nlm.nih.gov/pubmed/25047000 http://dx.doi.org/10.1186/1471-2202-15-90 |
_version_ | 1782329386763026432 |
---|---|
author | Rockenstein, Edward Ubhi, Kiren Trejo, Margarita Mante, Michael Patrick, Christina Adame, Anthony Novak, Philipp Jech, Marion Doppler, Edith Moessler, Herbert Masliah, Eliezer |
author_facet | Rockenstein, Edward Ubhi, Kiren Trejo, Margarita Mante, Michael Patrick, Christina Adame, Anthony Novak, Philipp Jech, Marion Doppler, Edith Moessler, Herbert Masliah, Eliezer |
author_sort | Rockenstein, Edward |
collection | PubMed |
description | BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical trials for AD, however it’s potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically. RESULTS: Compared to single Tau tg mice the Tau/GSK3β double tg model displayed elevated levels of Tau phosphorylation and neurodegeneration in the hippocampus. CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice. Interestingly, the Tau/GSK3β double tg mice also displayed elevated levels of Dynamin-related protein-1 (Drp-1), a protein that hydrolyzes GTP and is required for mitochondrial division. Ultrastructural analysis of the mitochondria in the Tau/GSK3β double tg mice demonstrated increased numbers and fragmentation of mitochondria in comparison to non-tg mice. CBL treatment normalized levels of Drp-1 and restored mitochondrial structure. CONCLUSIONS: These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial biogenesis associated with Tau. |
format | Online Article Text |
id | pubmed-4122761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41227612014-08-07 Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure Rockenstein, Edward Ubhi, Kiren Trejo, Margarita Mante, Michael Patrick, Christina Adame, Anthony Novak, Philipp Jech, Marion Doppler, Edith Moessler, Herbert Masliah, Eliezer BMC Neurosci Research Article BACKGROUND: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of dementia in the aging population for which limited therapeutical options are available. These disorders are associated with Tau accumulation. We have previously shown that Cerebrolysin(TM) (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical trials for AD, however it’s potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically. RESULTS: Compared to single Tau tg mice the Tau/GSK3β double tg model displayed elevated levels of Tau phosphorylation and neurodegeneration in the hippocampus. CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice. Interestingly, the Tau/GSK3β double tg mice also displayed elevated levels of Dynamin-related protein-1 (Drp-1), a protein that hydrolyzes GTP and is required for mitochondrial division. Ultrastructural analysis of the mitochondria in the Tau/GSK3β double tg mice demonstrated increased numbers and fragmentation of mitochondria in comparison to non-tg mice. CBL treatment normalized levels of Drp-1 and restored mitochondrial structure. CONCLUSIONS: These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial biogenesis associated with Tau. BioMed Central 2014-07-21 /pmc/articles/PMC4122761/ /pubmed/25047000 http://dx.doi.org/10.1186/1471-2202-15-90 Text en © Rockenstein et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Rockenstein, Edward Ubhi, Kiren Trejo, Margarita Mante, Michael Patrick, Christina Adame, Anthony Novak, Philipp Jech, Marion Doppler, Edith Moessler, Herbert Masliah, Eliezer Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title | Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title_full | Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title_fullStr | Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title_full_unstemmed | Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title_short | Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
title_sort | cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122761/ https://www.ncbi.nlm.nih.gov/pubmed/25047000 http://dx.doi.org/10.1186/1471-2202-15-90 |
work_keys_str_mv | AT rockensteinedward cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT ubhikiren cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT trejomargarita cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT mantemichael cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT patrickchristina cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT adameanthony cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT novakphilipp cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT jechmarion cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT doppleredith cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT moesslerherbert cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure AT masliaheliezer cerebrolysinefficacyinatransgenicmodeloftauopathyroleinregulationofmitochondrialstructure |